India’s pharmaceutical industry stands at a crossroads – between the comfort of volume-led generics and the discipline of innovation-driven value. For decades, India has worn the title of pharmacy of the world with justifiable pride. Affordable generic medicines, produced at scale, have served billions across developing nations. Yet pride, if unexamined, curdles into complacency. The structural paradox at the heart of Indian pharma – the world’s largest manufacturing base dependent on imported raw materials – is no longer a manageable inconvenience. It is a strategic vulnerability that hollows out the value of every tablet that rolls off the production line.
When active pharmaceutical ingredients are imported and finished formulations are exported, India’s pharma industry functions less as an innovator and more as an assembler. The margin captured is thin, the leverage is limited, and the supply chain risk is considerable. This model has run its course. As Union Minister J P Nadda rightly observed at India Pharma 2026, the global landscape is shifting decisively towards biologics, biosimilars and speciality medicines. These are not marginal segments – they are where future pricing power, intellectual property and global influence reside. Continuing to compete only on the back of low-cost generics, while failing to invest in R&D-led discovery, is to surrender tomorrow’s market in exchange for today’s volumes.
The government has signalled a genuine shift in intent. The Biopharma SHAKTI initiative, backed by a Rs 10,000 crore outlay over five years, alongside PLI schemes and bulk drug park development, represents a policy framework that rewards ambition. Plans to restructure CDSCO, build a network of 1,000 clinical trial sites, and recruit over 1,500 subject-matter experts in scientific review indicate an administration’s awareness of manufacturing demands. Equally urgent is the matter of quality. The rejection of Indian-manufactured drugs in multiple international markets has been damaging in ways that go beyond individual consignments. Infrastructure alone cannot resolve a culture of corner-cutting. Medical colleges and pharmaceutical firms must raise their research and quality assurance standards in tandem.
Pharmaceutical industry possesses the talent, the infrastructure and – increasingly – the policy support to make the transition from volume to value. What it still lacks, in too many boardrooms and too many campuses, is the conviction that the real profits lie not in replicating existing molecules cheaply, but in discovering new ones effectively. The Government has done its part in creating the enabling conditions. The challenge now belongs to the industry.
Follow our WhatsApp channel
